Participated · Equity · Aug 2026

Databricks operates a cloud data platform and AI products, with its core cloud data warehouse generating $1.5 billion of its annualized run-rate revenue and growing 100% year-over-year. The company reported a $7 billion annualized run-rate revenue figure while growing at roughly 80% and being cash-flow positive. Databricks launched Lakebase in June 2025, which has reached a $100 million revenue run-rate, and its AI chatbot tool Genie is described as highly popular. The company maintains a roughly 100-person AI research team and faces multi-billion-dollar cloud commitments with major hyperscalers. Databricks has been active on the M&A front, acquiring companies including Electric (PGlite) and AI cybersecurity firm Panther, and it says it plans to continue investing in AI and acquisitions while remaining open to a future IPO.

Participated · Equity · May 2026

Founded in April 2025 by former Freecharge CEO Jason Kothari, Mythik aims to adapt and globalize Eastern mythology, folktales and history using advanced technologies including AI and virtual production. The founding team includes former senior executives from Disney, Netflix, Amazon Studios, Jio and Tencent. The company is based in Mumbai and employs roughly 200 people across product, technology, content and design. Mythik recently completed a $5 million extension to a $15 million funding round, giving it a post-money valuation above $50 million. Investors in the extension include Harsh Jain, Rajat Gupta and Blume Founders Fund among others. Kothari previously acquired and sold Valiant Entertainment for $100 million in 2018, a detail highlighted in reporting on the startup.

Participated · Series G · Apr 2026

SiFive develops CPUs based on the open-source RISC-V instruction set aimed at large data center operators and hyperscalers. The company plans to offer rapidly customizable CPU solutions intended as alternatives to prevalent Nvidia AI accelerators and Arm-based server chips. SiFive intends to expand its software ecosystem to support its hardware offerings. In the funding announcement, SiFive said it will use newly raised capital to accelerate product and software development for AI data centers. The competitive landscape cited research estimating roughly 135 companies are developing or planning AI processors, with only about 25 expected to survive by 2030. SiFive's recent $400 million funding round values the company at $3.65 billion, reflecting its current financial backing.

Participated · Series C · Mar 2026

Nscale builds and operates vertically integrated AI data centers, controlling everything from renewable energy sourcing and facility construction to the compute stack and orchestration layer. Backed by Nvidia, the company is developing ‘Stargate Norway,’ an installation targeting 100,000 Nvidia GPUs by the end of 2026 with OpenAI as an initial customer. In October it also partnered with Microsoft and Dell to deploy roughly 200,000 Nvidia GPUs across four data centers in Europe and the U.S. The firm positions itself as a low-cost, green alternative for AI compute, pledging to reuse waste heat and invest in local skills and infrastructure. Its latest funding round values the company at $14.6 billion, placing it among Europe’s few AI decacorns. Nscale plans to use the new capital to accelerate build-outs in Europe, North America and Asia while expanding its engineering and operations teams. The company has hinted at a possible IPO as early as this year to further bolster its capital base. High-profile board appointments—including Sheryl Sandberg, Susan Decker and Nick Clegg—underscore its growing prominence.

Participated · Series B · Jan 2026

Mirador Therapeutics is focused on delivering first- and best-in-class therapeutics for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, idiopathic pulmonary fibrosis, and other immuno-fibrotic conditions. Its Mirador360 (M360) discovery and development engine combines more than 2.5 million patient profiles with advanced machine learning to uncover novel targets, stratify patients, and design rational drug combinations. In less than two years, the company has advanced multiple clinical-stage assets and is pursuing a parallel development strategy that aims to generate ten or more clinical readouts by the end of 2027. Management positions the approach as a step-change over incremental monotherapies, seeking to redefine precision medicine in immunology and inflammation. Mirador has raised over $650 million since launching in March 2024, enabling it to fund proof-of-concept studies across its current portfolio and add new pipeline candidates. The company operates with an emphasis on capital efficiency and disciplined execution to sustain momentum. Mirador is headquartered in San Diego, California.